Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy - Full Text View

Sponsors and Collaborators:	University of Utah Families of Spinal Muscular Atrophy Abbott
Information provided by:	University of Utah
ClinicalTrials.gov Identifier:	NCT00481013

Purpose

The primary objective of this proposal is to determine whether oral VPA is effective in treating SMA in adult patients.

Condition	Intervention	Phase
Spinal Muscular Atrophy	Drug: Valproic Acid (VPA) Drug: Placebo	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Efficacy Study
Official Title:	Prospective Controlled Trial of Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy (VALIANTSMA) Study

Resource links provided by NLM:

Genetics Home Reference related topics: spinal muscular atrophy

MedlinePlus related topics: Spinal Muscular Atrophy

Drug Information available for: Divalproex sodium Valproic acid Valproate Sodium

U.S. FDA Resources

Further study details as provided by University of Utah:

Primary Outcome Measures:

The primary outcome for the study is change in muscle strength from baseline to six months in muscle strength as assessed by MVICT using a fixed testing system. [ Time Frame: 13 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Change in SMAFRS [ Time Frame: 13 months ] [ Designated as safety issue: No ]
Change in strength assessed by hand-held dynamometer [ Time Frame: 13 months ] [ Designated as safety issue: No ]
Change in MUNE and CMAP [ Time Frame: 13 months ] [ Designated as safety issue: No ]
SMN2 copy number [ Time Frame: 13 months ] [ Designated as safety issue: No ]
Change in PFTs, including forced vital capacity (FVC) and negative inspiratory force (NIF) [ Time Frame: 13 months ] [ Designated as safety issue: No ]
Change in lean body mass through DEXA scanning [ Time Frame: 13 months ] [ Designated as safety issue: No ]
Change in distance walked in 6 minutes [ Time Frame: 13 months ] [ Designated as safety issue: No ]
Change in time to climb four standard stairs [ Time Frame: 13 months ] [ Designated as safety issue: No ]
Change in health-related QOL assessed through the modified sickness impact profile (SIP) [ Time Frame: 13 months ] [ Designated as safety issue: No ]

Estimated Enrollment:	36
Study Start Date:	July 2007
Estimated Study Completion Date:	August 2010
Estimated Primary Completion Date:	August 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1a: Placebo Comparator For six months, half of patients are randomized into placebo . After 6 months, all patients are on treatment.	Drug: Placebo For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
1b: Active Comparator Cohort 1b patients are randomized onto treatment. After 6 months, all patients are on drug.	Drug: Valproic Acid (VPA) Drug: Valproic Acid and Levocarnitine; capsules

Detailed Description:

Participation in this study entails six visits and seven to eight blood draws over 13 months. Each visit entails a stay of two days and one night at the General Clinical Research Center (GCRC).

Subjects who live within driving distance will be allowed to participate in the study without an overnight stay through two consecutive outpatient visits. All subjects will be evaluated at two screening visits 2-4 weeks apart to determine eligibility for participation. Eligible subjects will be randomized to receive VPA or placebo for the first six months. At the six-month visit, patients will be evaluated and crossed over to the other regimen.

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Ambulatory adults with SMA 3 ages 18-60. The diagnosis of SMA must be documented by the homozygous deletion of both SMN1 genes on standard genetic tests for the disorder. Patients must be able to walk thirty feet without assistance (i.e. no canes, walkers).
Interest in participating and the ability to meet the study requirements.
Women of child bearing age are required to be on birth control or abstain while participating in the study.

Exclusion Criteria:

Non-ambulatory type 3 adults and all type 2 adults.
Patients with co-morbid conditions that preclude travel, testing or study medications.
Patients who have participated in a treatment trial for SMA in the 3 months prior to this trial, or plan on enrolling in any other treatment trial during the duration of this trial.
Patients who are, in the investigator's opinion, mentally or legally incapacitated from providing informed consent for the study, or are otherwise unable to meet study requirements or cooperate reliably with study procedures, especially strength testing.
Patients with a need for non-invasive ventilatory support (e.g. BiPAP) for > 12 hours/day
Transaminases, amylase or lipase > 3.0 x normal values, WBC < 3.0 or neutropenia < 1.0, platelet count < 100 K, or hematocrit < 30 persisting over a 30 day period
Use of medications or supplements which interfere with VPA metabolism and increase the potential risks of the medications, or are hypothesized to have a beneficial effect in SMA animal models or human neuromuscular disorders within 3 months of study enrollment. These agents include riluzole, creatine, butyrate derivatives, growth hormone, anabolic steroids, daily albuterol use, anticonvulsants, or other HDAC inhibitors.
Women who are pregnant or who intend to become pregnant while participating in the research study or who are breastfeeding.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00481013

Contacts

Contact: Sharon Chelnick, .

614-293-4973

Locations

United States, Ohio
Ohio State University Medical Center, Dept. of Neurology	Recruiting
Columbus, Ohio, United States, 43210
Contact: Sharon Chelnick 614-293-4973
Principal Investigator: John T Kissel

Sponsors and Collaborators

University of Utah

Families of Spinal Muscular Atrophy

Abbott

Investigators

Principal Investigator:	John T Kissel	Ohio State University
Study Director:	Sandra P Reyna, M.D.	Families of Spinal Muscular Atrophy
Principal Investigator:	Kathryn J Swoboda, M.D.	University of Utah

More Information

No publications provided

Responsible Party:	Ohio State University Medical Center ( John T. Kissel )
Study ID Numbers:	2006H0249
Study First Received:	May 30, 2007
Last Updated:	July 17, 2009
ClinicalTrials.gov Identifier:	NCT00481013 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Utah:

Spinal Muscular Atrophy
Adult

Study placed in the following topic categories:

Pathological Conditions, Anatomical
Neurotransmitter Agents
Tranquilizing Agents
Spinal Cord Diseases
Psychotropic Drugs
Spinal Muscular Atrophy
Central Nervous System Depressants
Central Nervous System Diseases
Antimanic Agents
Neurodegenerative Diseases
Valproic Acid

Signs and Symptoms
Neuromuscular Diseases
Muscular Atrophy, Spinal
Neurologic Manifestations
Atrophy
Degenerative Motor System Disease
Motor Neuron Disease
Anticonvulsants
Carnitine
Muscular Atrophy
Progressive Spinal Muscular Atrophy

Additional relevant MeSH terms:

Pathological Conditions, Anatomical
Neurotransmitter Agents
Spinal Cord Diseases
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Neurodegenerative Diseases
Valproic Acid
Signs and Symptoms
Neuromuscular Diseases
Muscular Atrophy, Spinal
Therapeutic Uses
Motor Neuron Disease
Muscular Atrophy

Neuromuscular Manifestations
Tranquilizing Agents
Nervous System Diseases
Central Nervous System Diseases
Central Nervous System Depressants
Enzyme Inhibitors
Antimanic Agents
Pharmacologic Actions
GABA Agents
Neurologic Manifestations
Atrophy
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on September 11, 2009